Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "S-1"

772 News Found

Wellness Forever Medicare expands its presence as it opens 15 new stores
Healthcare | August 18, 2021

Wellness Forever Medicare expands its presence as it opens 15 new stores

It strengthens its presence to over 250 stores


Centre releases Rs 1,300 crores to Northeast states to fight Covid-19
Policy | August 18, 2021

Centre releases Rs 1,300 crores to Northeast states to fight Covid-19

The funds will be used to buy medicines, enhance oxygen supply and augment the bed capacity in the local and district level hospitals


Fermenta Biotech PAT at Rs 11.54 cr. for Q1FY22
Biotech | August 14, 2021

Fermenta Biotech PAT at Rs 11.54 cr. for Q1FY22

EPS at Rs 3.92


Ind-Swift Laboratories PAT at Rs 18.80 cr for Q1FY22
News | August 13, 2021

Ind-Swift Laboratories PAT at Rs 18.80 cr for Q1FY22

EPS stood at Rs 3.18


Hester Biosciences posts PAT of Rs 11.01 cr in Q1FY22
News | August 12, 2021

Hester Biosciences posts PAT of Rs 11.01 cr in Q1FY22

The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.


AstraZeneca Pharma India PAT at Rs 10.24 crores
Biotech | August 09, 2021

AstraZeneca Pharma India PAT at Rs 10.24 crores

Board declares interim dividend of Rs 2 per equity share


PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya
Policy | August 03, 2021

PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya

The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales


Astec Lifesciences 1FY22 consolidated PAT at Rs. 12.98 Cr
News | July 29, 2021

Astec Lifesciences 1FY22 consolidated PAT at Rs. 12.98 Cr

The company posted net profit of Rs.16.18 crores for the period ended June 30, 2020.


GlaxoSmithKline delivers 19% revenue growth for Q1 FY22
News | July 27, 2021

GlaxoSmithKline delivers 19% revenue growth for Q1 FY22

The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited


Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
News | July 23, 2021

Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr

Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).